Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study

Andrew Whittaker, Åsa M. Kragh, Judith Hartlieb-Geschwindner, Muna Albayaty, Anna Backlund, Peter J. Greasley, Maria Heijer, Magnus Kjaer, Pablo Forte, Robert Unwin, Linda Wernevik and Hans Ericsson

Excessive activation of the mineralocorticoid receptor (MR) underlies the pathophysiology of heart failure and chronic kidney disease. Hyperkalemia risk limits the therapeutic use of conventional MR antagonists. AZD9977 is a nonsteroidal, selective MR modulator that may protect nonepithelial tissues without disturbing electrolyte balance. This phase I study investigated the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of AZD9977 in healthy volunteers. Twenty-seven male participants aged 23–45 years were randomized 3:1 to receive oral AZD9977 or placebo for 8 days (with twice-daily dosing on days 2–7), in dose cohorts of 50, 150, and 300 mg (AZD9977, n = 6 per cohort; placebo, n = 3 per cohort). Adverse events occurred in 4 of 18 participants receiving AZD9977 (22.2%) and 6 of 9 receiving placebo (66.7%), all of mild or moderate severity; none were serious or led to withdrawal. AZD9977 was rapidly absorbed, with median time of maximum concentration of 0.50–0.84 hours across dose groups. Area under the curve and maximum concentration were approximately dose proportional but elimination and accumulation terminal half-life increased with dose. Steady-state was reached after 3–4 days, with dose-dependent accumulation of 1.2–1.7-fold. Renal clearance was 5.9–6.5 L/hour and 24–37% of AZD9977 was excreted in the urine. Serum aldosterone levels increased dose dependently from days −1 to 7 in participants receiving AZD9977, but serum potassium levels and urinary electrolyte excretion were unchanged. AZD9977 was generally well-tolerated with no safety concerns. Exploratory outcomes suggested reduced hyperkalemia risk compared with MR antagonists. These findings support further clinical development of AZD9977.

Heart failure affects ~ 1–2% of the global population, and chronic kidney disease (CKD) occurs in ~ 11–15%. The prevalence of both these diseases is increasing with the global epidemic of obesity, diabetes, hypertension, and an aging population. Approximately half of all patients with heart failure have heart failure with preserved ejection fraction (HFpEF), and there are no treatments available that have conclusively been shown to reduce mortality or to...
Clinical and Translational Science

Whittaker et al.

Initial Clinical Experience with AZD9977

OBJECTIVES

Overview and objectives

This was a randomized, placebo-controlled, single-blind phase I study of the safety, tolerability, and pharmacokinetics of AZD9977 in sequential ascending dose groups of healthy men receiving oral AZD9977 for 8 days. Participants were blinded to treatment assignment and study site staff were blinded during clinical conduct of each cohort. The primary objective of the study was to investigate the safety and tolerability of AZD9977 after multiple dosing. The secondary objectives were to characterize the pharmacokinetics of AZD9977, including assessments of the time needed to reach steady-state plasma levels of the drug, the extent of drug accumulation in the body, and the dependence of pharmacokinetic parameters on time.

Exploratory objectives were to assess the effects of AZD9977 on serum and urinary electrolyte levels, serum aldosterone levels, and plasma 4β-hydroxycholesterol levels. Monitoring 4β-hydroxycholesterol levels in the first multiple-dose study in humans is part of the published AstraZeneca strategy for assessing potential CYP3A induction with investigational new drugs. 

METHODS

Conduct and ethics

An independent ethics committee (National Research Ethics Service South Central – Berkshire B, UK) and regulatory authority (Medicines and Healthcare Products Regulatory Agency, UK) reviewed and approved the study protocol and its amendments. The study was conducted in accordance with the principles of the Declaration of Helsinki and the International Council for Harmonisation Good Clinical Practice guidelines, and is registered on ClinicalTrials.gov (identifier: NCT03435276). All participants gave freely their written informed consent before starting the study. The study took place from February to June 2018 at the PAREXEL Early Phase Clinical Unit in Northwick Park Hospital, London, UK.

Participants were blinded to treatment assignment and study site staff were blinded during clinical conduct of each cohort. The primary objective of the study was to investigate the safety and tolerability of AZD9977 after multiple dosing. The secondary objectives were to characterize the pharmacokinetics of AZD9977, including assessments of the time needed to reach steady-state plasma levels of the drug, the extent of drug accumulation in the body, and the dependence of pharmacokinetic parameters on time.

Initial Clinical Experience with AZD9977

Whittaker et al.

Initial Clinical Experience with AZD9977

Whittaker et al.

METHODS

Overview and objectives

This was a randomized, placebo-controlled, single-blind phase I study of the safety, tolerability, and pharmacokinetics of AZD9977 in sequential ascending dose groups of healthy men receiving oral AZD9977 for 8 days. Participants were blinded to treatment assignment and study site staff were blinded during clinical conduct of each cohort. The primary objective of the study was to investigate the safety and tolerability of AZD9977 after multiple dosing. The secondary objectives were to characterize the pharmacokinetics of AZD9977, including assessments of the time needed to reach steady-state plasma levels of the drug, the extent of drug accumulation in the body, and the dependence of pharmacokinetic parameters on time.

Exploratory objectives were to assess the effects of AZD9977 on serum and urinary electrolyte levels, serum aldosterone levels, and plasma 4β-hydroxycholesterol levels. Monitoring 4β-hydroxycholesterol levels in the first multiple-dose study in humans is part of the published AstraZeneca strategy for assessing potential CYP3A induction with investigational new drugs. 

METHODS

Conduct and ethics

An independent ethics committee (National Research Ethics Service South Central – Berkshire B, UK) and regulatory authority (Medicines and Healthcare Products Regulatory Agency, UK) reviewed and approved the study protocol and its amendments. The study was conducted in accordance with the principles of the Declaration of Helsinki and the International Council for Harmonisation Good Clinical Practice guidelines, and is registered on ClinicalTrials.gov (identifier: NCT03435276). All participants gave freely their written informed consent before starting the study. The study took place from February to June 2018 at the PAREXEL Early Phase Clinical Unit in Northwick Park Hospital, London, UK.

Participants were blinded to treatment assignment and study site staff were blinded during clinical conduct of each cohort. The primary objective of the study was to investigate the safety and tolerability of AZD9977 after multiple dosing. The secondary objectives were to characterize the pharmacokinetics of AZD9977, including assessments of the time needed to reach steady-state plasma levels of the drug, the extent of drug accumulation in the body, and the dependence of pharmacokinetic parameters on time.

Exploratory objectives were to assess the effects of AZD9977 on serum and urinary electrolyte levels, serum aldosterone levels, and plasma 4β-hydroxycholesterol levels. Monitoring 4β-hydroxycholesterol levels in the first multiple-dose study in humans is part of the published AstraZeneca strategy for assessing potential CYP3A induction with investigational new drugs. 

Additionally, an oral
glucose tolerance test (OGTT) was performed on day −1 and day 7, because a small reversible increase in plasma glucose level was observed in preclinical rat toxicology studies (all values within the normal range).

**Participants**
Male volunteers aged 18–50 years, weighing 50–100 kg, and with a body mass index of 18–30 kg/m² were eligible for the study. Key exclusion criteria were: history or presence of any disease or disorder that might influence study participation or results; history or presence of any condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs, including gastrointestinal, hepatic, or renal disease; any clinically significant illness, medical procedure, or trauma within the previous 4 weeks; any clinically important abnormalities in clinical chemistry, hematology, or urinalysis (including serum potassium > 5.0 mmol/L and glycated hemoglobin > 5.7%); abnormal vital signs (including systolic blood pressure < 90 mmHg or > 140 mmHg, diastolic blood pressure < 50 mmHg or > 90 mmHg, and heart rate < 45 or > 85 beats per minute); or any clinically important electrocardiographic abnormalities. Volunteers who tested positive for nicotine, alcohol, or recreational drugs were ineligible, as were those with excessive caffeine intake.

**Randomization and blinding**
Participants were divided into three sequential ascending dose cohorts (n = 9 per cohort). Within each cohort, participants were randomized to receive AZD9977 (n = 6) or placebo (n = 3). This was a single-blind study in which study center staff were also blinded to treatment assignment during the clinical conduct of each cohort. AZD9977 and placebo matched in formulation, appearance, and administration volume. Safety data from each sequential dose cohort were reviewed unblinded. Treatment assignment could be revealed if necessary in a medical emergency.

**Study drug administration**
In each cohort of nine participants, dosing started with two sentinel participants (AZD9977, n = 1; and placebo, n = 1) and continued in the remaining participants after review of safety data from the sentinel participants at 72 hours after their first dose. Participants resided at the study center from 2 days before their first dose until at least 36 hours after their last dose and attended a follow-up visit 5–7 days after their last dose. Screening took place within 28 days of admission.

In the first cohort, each participant received oral AZD9977 50 mg or matching placebo from day 1 to day 8, with single doses on day 1 and day 8 and twice-daily dosing on days 2–7 (a total of 14 doses). Doses were escalated to AZD9977 150 and 300 mg in the subsequent cohorts after review of safety and pharmacokinetic data from previous cohorts. The starting dose was based on preclinical pharmacokinetic–pharmacodynamic modeling data and on the previous observation that single doses of AZD9977 up to 1,200 mg were well-tolerated in healthy men. AZD9977 was administered as a 15 mg/mL oral suspension in a volume of 240 mL.

On day 1 and day 8, participants fasted for 10 hours before morning dosing and until 4 hours after dosing, when lunch was served. On days 2–7, participants fasted for 10 hours before morning dosing and until 1 hour after morning dosing, when breakfast was served; and from 2 hours before evening dosing until 1 hour after evening dosing. Participants could drink freely except during the 1 hour before and after dosing. No concomitant medication was allowed during the study other than paracetamol (acetaminophen), including herbal remedies, vitamin supplements, and over-the-counter products. While resident at the study center, participants received a standard diet that excluded alcohol and products containing grapefruit. Participants refrained from lying fully supine for 4 hours after dosing (unless required for study assessments) and refrained from strenuous activity from 72 hours before admission to the study center until follow-up.

**Safety assessments**
Safety was assessed throughout the study by monitoring adverse events, cardiac telemetry, vital signs, and electrocardiographic parameters, conducting physical examinations and laboratory analyses, and collecting urine to measure electrolyte excretion. Criteria for stopping the study on the grounds of safety were predefined. The safety analysis set included all participants who received at least one dose of AZD9977 or placebo.

**Pharmacokinetic analyses**
Plasma was collected for pharmacokinetic analyses before all doses and at 20 minutes, 40 minutes, and 1, 2, 4, 6, 8, 10, 12, 16, and 20 hours after dosing on day 1 and day 8, then at 24, 30, and 36 hours after the final dose. Urine samples were collected on day 8 (before and 0–4, 4–8, and 8–12 hours after dosing).

Plasma pharmacokinetic outcomes included the observed maximum concentration (C max), time to C max (T max), t 1/2 associated with terminal slope (λz) of a semilogarithmic concentration–time curve (t 1/2z), t 1/2 based on drug accumulation at steady state (t 1/2acc), area under the concentration–time curve extrapolated to infinity (AUC0–∞) and in the dosing period (AUCp), apparent clearance (CL/F), renal clearance (CLR), and accumulation ratio (F acc). Actual blood sampling times were used in all analyses and plasma concentration over time data were analyzed by nonparamaternal analysis with Phoenix WinNonlin (version 6.2 Pharsight, Mountain View, CA). The pharmacokinetic analysis set included all participants in the safety set with calculable pharmacokinetic data for at least two treatment periods and without protocol deviations that might have affected pharmacokinetic data.

**Exploratory outcomes**
Glucose homeostasis was assessed by OGTT on day −1 and immediately after dosing on day 7. Blood samples for analysis of glucose, insulin, and C-peptide were taken before and 2 hours after the administration of oral glucose at the same time of day on the 2 test days. Participants fasted overnight before testing and continued to fast until testing was complete.

Blood samples were taken for measurement of electrolyte and aldosterone levels immediately before administration of
oral glucose on day −1 and day 7. Urinary electrolytes were assessed for 12 hours after administration of oral glucose on day −1 and day 7, using urine collection intervals of 0–3, 3–6, 6–9, and 9–12 hours after administration.

Induction of CYP450 3A4/3A5 was assessed by sampling blood for measurement of 4ß-hydroxycholesterol levels before dosing on day 1 and day 8.

Bioanalysis of blood and urine samples
Urine and plasma samples for analysis of AZD9977 and 4ß-hydroxycholesterol concentrations were stored at −20°C until analysis within the known stability period. Samples were analyzed by Covance Laboratories (Harrogate, UK). AZD9977 and the stable-labeled internal standard [13CD3]AZD9977 were extracted from plasma by protein precipitation and from urine by sample dilution, before analysis by liquid chromatography and tandem mass spectrometry. The methods were validated in the range 10–10,000 nmol/L before sample analysis. Inter-run accuracy and precision were in the ranges of 99.0–100.6% and 1.3–7.2% for plasma and 99.5–100.8% and 1.1–6.7% for urine, respectively, at concentrations of 10, 30, 500, 8,000, and 25,000 nmol/L in plasma and urine. Each analytical run included a calibration curve, appropriate blanks, and duplicate quality control samples at three concentrations within the calibration range. During the study, incurred sample reproducibility analyses showed that 72 of 72 plasma (100%) and 20 of 20 urine (100%) samples tested were within 20% of the mean of the two values, which fulfilled criteria for acceptable performance. Levels of 4ß-hydroxycholesterol in plasma were analyzed as previously reported. Other biomarkers were assayed using standard clinical laboratory methods.

Statistical methods
This sample size was chosen based on previous experience of phase I studies to obtain reasonable evidence of safety and tolerability without unnecessary exposure of healthy volunteers to the investigational drug. Sample size was not based on statistical power calculation.

RESULTS

Participant disposition and demographics
All 27 randomized participants completed the study and were included in the safety and pharmacokinetic analysis sets (Figure 1). The 18 participants randomized to AZD9977 received doses of 50, 150, or 300 mg with twice-daily dosing on days 2–7 (six per cohort) and the remaining nine participants received placebo (three per cohort). All participants were men aged 23–45 years and most were white (Table 1).

Safety and tolerability
Multiple ascending oral doses of AZD9977 up to 300 mg twice daily were well-tolerated and no safety concerns were raised. There were no serious adverse events or deaths. Seven adverse events occurred in 4 of the 18 participants (22.2%) receiving AZD9977, and eight events occurred in six of the nine participants (66.7%) receiving placebo. All adverse events were of mild or moderate intensity, and none resulted in withdrawal from the study. In the AZD9977 groups, three adverse events were reported in the 50 mg group (headache, two events; cellulitis, one event), two in the 150 mg group (back pain, one event; dizziness, one event), and two in the 300 mg group (musculoskeletal chest pain, one event; ear discomfort, one event). In the placebo group, the adverse events reported were headache (three events), swelling (one event), seasonal allergy (one event), nasal congestion (one event), and contact dermatitis (two events). Only the headache events were considered related to the study drug by the investigator. No clinically meaningful changes in blood pressure, heart rate, or laboratory values were observed with AZD9977 (including serum sodium, potassium, bicarbonate, and calcium levels).

Pharmacokinetics
AZD9977 was rapidly absorbed after oral administration, with a median T\textsubscript{max} in the range 0.50–0.84 hours on both day 1 (Figure 2a) and day 8 (Figure 2b) across all dose groups (Table 2). The t\textsubscript{1/2} of AZD9977 increased with dose, from a mean of 4.44 hours in the 50 mg group to 9.62 hours in the 300 mg group on day 8 (Table 2).
The percentage of the AZD9977 dose excreted in the urine ranged from 24.37%, with renal clearance in the range 5.89–6.48 L/hour across doses. The AUC$_{\tau}$ and C$_{\text{max}}$ of AZD9977 were approximately proportional to dose on day 8, with modeled slope estimates of 0.871 (90% confidence interval, 0.624–1.12) and 1.04 (0.822–1.26), respectively. Steady-state was reached within 3–4 days of twice-daily dosing with AZD9977, with dose-dependent accumulation of 1.2-fold to 1.7-fold across the dose range (Rac and t$_{1/2\text{acc}}$; Table 2) and higher trough concentration (C$_{\text{trough}}$) values in the morning compared with the evening (Figure 3).

Figure S1 shows AZD9977 concentration–time profiles in individual participants.

**Exploratory outcomes**

**Aldosterone and electrolyte levels.** Serum aldosterone levels increased dose dependently from day −1 to day 7 in participants receiving AZD9977, with no change in the placebo group (Figure 4a; Table S1). Serum potassium levels did not undergo any clinically meaningful changes throughout the study (Figure 4b; Figure S2). Urinary electrolyte excretion was not affected in any AZD9977 dose cohort, with similar log ratios of sodium to potassium levels for participants receiving AZD9977 and placebo under fasted conditions on day 7 (Figure 5). Electrolyte ratios were also similar to those observed on day −1 under uncontrolled feeding conditions (Figure 5).

**Glucose homeostasis.** AZD9977 doses up to 300 mg twice daily had no effect on glucose homeostasis based on the OGTT (data not shown).

**CYP450 3A4/3A5 induction.** No increases in 4β-hydroxycholesterol levels were observed, with mean changes from before dosing on day 1 to day 7 of −3.28 ng/mL (SD, 1.99), −4.98 ng/mL (SD, 1.54), and −4.82 ng/mL (SD, 5.14) for AZD9977 doses of 50, 150, and 300 mg, respectively.

**DISCUSSION**

In this phase I study, multiple oral doses of AZD9977 up to 300 mg for 8 days, with twice-daily dosing on days 2–7, were...
well-tolerated by healthy male volunteers, with no safety or tolerability concerns identified. Plasma levels of AZD9977 reached steady-state after 3–4 days. Following twice-daily dosing, C\text{trough} values were higher in the morning than the evening, likely owing to an effect of food intake on absorption. Accumulation and t\text{1/2}\text{λ}\text{z} both increased with dose of AZD9977, for reasons that are not fully understood. The limited solubility of AZD9977 and the ongoing absorption of the previous dose in the colon, rather than dose-dependent and/or time-dependent disposition, may explain these findings. Consistent with this possibility, plasma levels of AZD9977 declined more rapidly from ~24 to 36 hours after the last dose on day 8 than from 12 to 24 hours after dosing (Figure 2b, Figure S1). Additional support for this explanation is the similar dose proportionality in exposure on day 1 and day 8, the time needed to reach steady-state, and the stable morning and evening C\text{trough} levels at steady-state. Moreover, regional absorption of AZD9977 was explored in a previous study and the extent of colonic absorption was reported to be sufficient for development of a controlled release formulation. AZD9977 did not increase 4β-hydroxycholesterol levels, indicating no induction of CYP450 3A4/3A5.

Serum aldosterone levels increased dose dependently in participants receiving AZD9977, indicating effective target engagement of the MR (Figure 4a). Administration of AZD9977 and the associated increases in serum aldosterone levels were not, however, accompanied by any alteration in urinary electrolyte excretion or serum levels of potassium or other electrolytes (Figure 4b, Figure 5). These results are consistent with a differentiated mechanism of action of AZD9977 when compared with other MR antagonists and are in agreement with the findings in rats fed a low-salt diet, in which AZD9977 also had no effect on the urinary sodium to potassium ratio. The observations made in this study suggest AZD9977 has a unique mode of action supporting early reported findings of MR modulation rather than antagonism. In contrast, with eplerenone,
dose-related increases in serum aldosterone levels were accompanied by significant increases in the urinary sodium to potassium ratio after administration of single doses of 100–1000 mg to healthy volunteers. Moreover, transient reductions in serum sodium levels and increases in serum potassium levels were observed after administration of multiple doses of eplerenone 100–1000 mg.30,31 However, some of these studies were performed under conditions of a low sodium (20 mmol/day) or a restricted sodium (150 mmol/day) and potassium (80 mmol/day) diet, in order to promote distal sodium reabsorption, in contrast to this study in which daily sodium intake was in the normal range.30,32

Following fludrocortisone agonist challenge in a previous phase I trial in healthy volunteers, a single dose of AZD9977 unexpectedly increased the urine sodium to potassium ratio to a similar degree to eplerenone.26 In rats, AZD9977 also increased the urinary sodium to potassium ratio after fludrocortisone challenge, but did not affect the sodium to potassium ratio after aldosterone challenge through either administration of exogenous aldosterone or elevation of endogenous aldosterone levels.33 In contrast, eplerenone increased the urinary sodium to potassium ratio after both fludrocortisone and exogenous aldosterone challenge in rats.33 These findings suggest that fludrocortisone affects kidney electrolyte handling differently from aldosterone, possibly because fludrocortisone activates the glucocorticoid receptor as well as the MR at the doses administered in the phase I trial and the rodent studies.33 Given that AZD9977 is thought to modulate the MR,25 fludrocortisone challenge in healthy volunteers may not be a suitable model for predicting effects of AZD9977 in patients with aldosterone-mediated conditions, such as heart failure.

The target engagement demonstrated in the present study while potassium levels remained stable in the blood and urine of healthy volunteers is consistent with the potential of AZD9977 to effectively treat patients with cardiac and renal disease, with a reduced risk of hyperkalemia compared with MR antagonists. However, healthy participants may be less prone to hyperkalemia associated with MR modulation than patients with heart failure or CKD, so the effect of AZD9977 on potassium retention needs to be confirmed in target patient populations. A phase I study is ongoing to compare the effect of AZD9977 with that of spironolactone on serum potassium levels in patients with heart failure with preserved or mid-range ejection fraction, and renal impairment (ClinicalTrials.gov identifier: NCT03682497).

The strengths of the current study include the enrollment of the minimum possible number of healthy volunteers to obtain reasonable evidence of safety and tolerability, and the comprehensive safety, pharmacokinetic, and pharmacodynamic assessments conducted. A key limitation of this study
was that potassium retention was not investigated after MR agonist challenge or during elevation of endogenous aldosterone levels, for example, via a low-salt diet. The analyses of urine electrolytes on day –1 and day 7 may have been compromised by the lack of dietary standardization on day –1.

**CONCLUSIONS**

In this phase I study of AZD9977, no safety or tolerability concerns were identified in healthy volunteers receiving oral doses up to 300 mg for 8 days (with twice-daily dosing on days 2–7). Furthermore, no significant effects on either serum potassium levels or urinary sodium excretion were observed, despite dose-dependent elevations in serum aldosterone levels. The aldosterone response to AZD9977 supports target engagement, and the lack of effect on electrolytes is consistent with its hypothesized mechanism of action. The study confirmed the safety profile and pharmacodynamic effects of AZD9977 observed in a previous single-dose phase I study in healthy volunteers. The results of these studies suggest that AZD9977 may protect against aldosterone-mediated organ damage, with a reduced risk of hyperkalemia compared with MR antagonists. These findings support further clinical development of AZD9977 in patients with HFpEF, as well as those with CKD.

**Supporting Information.** Supplementary information accompanies this paper on the Clinical and Translational Science website (www.cts-journal.com).

**Figure S1.** AZD9977 concentration–time profiles for individual participants on day 1 after receiving AZD9977 (a) 50 mg, (b) 150 mg, and (c) 300 mg, and on day 8 after receiving AZD9977 (d) 50 mg, (e) 150 mg, and (f) 300 mg.

**Figure S2.** Change in serum potassium level from day –1. Data are mean ± SD from the safety analysis set. Data points are horizontally offset for clarity.

**Table S1.** Serum aldosterone levels.

**Acknowledgments.** The authors thank the volunteers, investigators, and site staff who participated in this study. We thank Adele Buss, PhD, from Oxford PharmaGenesis, Oxford, UK, who provided medical writing support funded by AstraZeneca. AZD9977 is an investigational medical product with no approved indication.

**Funding.** AstraZeneca provided funding to PAREXEL for the conduct of this study.

**Conflict of Interest.** A.W., A.M.K., J.H.-G., A.B., P.J.G., M.H., M.K., R.U., L.W., and H.E. are employees of AstraZeneca, and may own stock or stock options. M.A. and P.F. are employees of PAREXEL.

**Author Contributions.** All authors wrote the manuscript. A.W., A.M.K., J.H.-G., A.B., P.J.G., M.H., R.U., L.W., H.E., and M.K. designed the research. M.A. and P.F. performed the research. All authors analyzed the data.

**Data Availability Statement.** Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca’s data sharing policy described at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

1. Savarese, G. & Lund, L.H. Global public health burden of heart failure. *Card Fail. Rev. 3, 7–11* (2017).
2. Hill, N.R. et al. Global prevalence of chronic kidney disease – a systematic review and meta-analysis. *PloS One 11*, e0168765 (2016).
3. Kovesdy, C.P., Furth, S.L., Zoccali, C. & World Kidney Day Steering Committee. Obesity and kidney disease: hidden consequences of the epidemic. *Am. J. Nephrol. 45*, 283–291 (2017).
4. Roger, V.L. Epidemiology of heart failure. *Circ. Res. 113*, 646–659 (2013).
5. Ponikowski, P. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur. Heart J. 37*, 2129–2200 (2016).
6. Ter Maaten, J.M. et al. Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation. *Eur. J. Heart Fail. 18*, 588–598 (2016).
7. Gilbert, K.C. & Brown, N.J. Aldosterone and inflammation. *Curr. Opin. Endocrinol. Diabetes Obes. 17*, 199–204 (2010).
8. Tesch, G.H. & Young, M.J. Mineralocorticoid receptor signaling as a therapeutic target for renal and cardiac fibrosis. *Front. Pharmacol. 8*, 313 (2017).
9. Gekle, M. & Grossmann, C. Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly? *Phygears Arch. 458*, 231–246 (2009).
10. He, B.J. & Anderson, M.E. Aldosterone and cardiovascular disease: the heart of the matter. *Trends Endocrinol. Metab. 24*, 21–30 (2013).
11. Buonafine, M., Bonnard, B. & Jaissier, F. Mineralocorticoid receptor and cardiovascular disease. *Am. J. Hypertens. 31*, 1165–1174 (2018).
12. Weber, K.T. Aldosterone in congestive heart failure. *N. Engl. J. Med. 345*, 1689–1697 (2001).
13. Free, E.M. & Connell, J.M. Mechanisms of hyper tension: the expanding role of aldosterone. *J. Am. Soc. Nephrol. 15*, 1993–2001 (2004).
14. Pitt, B. et al. Spironolactone for heart failure with preserved ejection fraction. *N. Engl. J. Med. 370*, 1383–1392 (2014).
15. Bonsu, K.O., Arumana, P. & Chaiyakunapruk, N. Pharmacological treatments for heart failure with preserved ejection fraction – a systematic review and indirect comparison. *Heart Fail. Rev. 23*, 147–158 (2018).
16. Pitt, B., Pedro, J. & Zambanini, F. Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives. *Eur. J. Cardiovasc. Pharmacother. 3*, 48–57 (2017).
17. Pfeffer, M.A. et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. *Circulation 131*, 34–42 (2015).
18. Bianchi, S., Bigazzi, R. & Campese, V.M. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. *Kidney Int. 70*, 2116–2123 (2006).
19. Bertocchio, J.P., Warnock, D.G. & Jaissier, F. Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. *Kidney Int. 79*, 105–1069 (2011).
20. Bolignano, D., Palmer, S.C., Navaneethan, S.D. & Strippoli, G.F. Aldosterone antagonists for preventing the progression of chronic kidney disease. *Cochrane Database Syst. Rev. CD007004* (2014).
21. Sarwar, C.M. et al. Hyperkalemia in heart failure. *J. Am. Coll. Cardiol. 68*, 1575–1589 (2016).
22. Ferreira, J.P. et al. Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF. *Eur. J. Heart Fail. 19*, 1284–1283 (2017).
23. Abbas, S., Thee, P., Harder, S. & Schubert, I. Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort. *Pharmacoeconomics. Drug Saf. 24*, 406–413 (2015).
24. Trevisan, M. et al. Incidence, predictors and clinical management of hyperkalemia in new users of mineralocorticoid receptor antagonists. *Eur. J. Heart Fail. 20*, 1217–1226 (2018).
25. Bamberg, K. et al. Preclinical pharmacology of AZD9977: a novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion. *PloS One 13*, e0193380 (2018).
26. Eriandsson, F. et al. Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator. *Br. J. Clin. Pharmacol. 84*, 1486–1493 (2018).
27. International Council for Harmonisation. ICH Harmonised Tripartite Guideline. *Guideline for Good Clinical Practice E6(R1) Current Step 4 version, dated June 10, 1996: <https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/EE/6_E6_R1_Guideline.pdf>. Accessed April 12, 2019.
28. Jones, B.C. et al. Managing the risk of CYP3A induction in drug development: a strategic approach. *Drug Metab. Dispos. 45*, 35–41 (2017).
29. van de Marbel, N.C., Bronsena, K.J., van Hout, M.W., Nilsson, R. & Sillen, H. A validated liquid chromatography-tandem mass spectrometry method for the quantitative determination of 48-hydroxycholesterol in human plasma. *J. Pharm. Biomed. Anal. 55*, 1089–1095 (2011).
30. Eudy, R.J. et al. The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism. *J. Transl. Med.* 9, 180 (2011).

31. Thosar, S.S., Gokhale, R.D. & Tolbert, D.S. Micronized eplerenone compositions. US Patent US7157101B2, 2007: <https://patents.google.com/patent/US7157101>. Accessed August 28, 2019.

32. Preston, R.A., Afshartous, D., Rodo, R., Alonso, A.B. & Garg, D. Evidence for a gastrointestinal-renal kaliuretic signaling axis in humans. *Kidney Int.* 86, 1393–1391 (2015).

33. Bamberg, K., William-Olsson, L., Johansson, U., Jansson-Lofmark, R. & Hartleb-Geschwindner, J. The selective mineralocorticoid receptor modulator AZD9977 reveals differences in mineralocorticoid effects of aldosterone and fludrocortisone. *J. Renin Angiotensin Aldosterone Syst.* 20, 1–6 (2019).

© 2019 The Authors. *Clinical and Translational Science* published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.